Wells Fargo & Company Raises Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $42.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its target price boosted by stock analysts at Wells Fargo & Company from $30.00 to $42.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's target price suggests a potential upside of 49.52% from the company's current price.

Other equities analysts also recently issued reports about the company. Wedbush restated an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Citigroup began coverage on Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Finally, Jefferies Financial Group lifted their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of "Buy" and an average target price of $39.33.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ:KNSA traded down $0.86 during mid-day trading on Wednesday, reaching $28.09. The stock had a trading volume of 355,269 shares, compared to its average volume of 556,024. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -112.36 and a beta of 0.05. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $30.69. The stock's 50 day simple moving average is $27.71 and its two-hundred day simple moving average is $23.10.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. Kiniksa Pharmaceuticals International's quarterly revenue was up 72.5% compared to the same quarter last year. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 15,211 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $28.75, for a total transaction of $437,316.25. Following the sale, the chief accounting officer owned 32,546 shares of the company's stock, valued at $935,697.50. The trade was a 31.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ross Moat sold 27,594 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total value of $800,777.88. Following the sale, the insider directly owned 9,415 shares in the company, valued at approximately $273,223.30. The trade was a 74.56% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 440,863 shares of company stock valued at $12,101,029. Company insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in shares of Kiniksa Pharmaceuticals International by 33.1% in the fourth quarter. Bank of New York Mellon Corp now owns 122,051 shares of the company's stock valued at $2,414,000 after buying an additional 30,382 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Kiniksa Pharmaceuticals International by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock valued at $2,414,000 after buying an additional 32,393 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at $3,955,000. Globeflex Capital L P increased its holdings in shares of Kiniksa Pharmaceuticals International by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock valued at $1,752,000 after buying an additional 60,656 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of Kiniksa Pharmaceuticals International by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after buying an additional 719 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.